海南康哲美丽科技

CMS Aesthetics (Hainan Kangzhe Meili Technology) is the specialized dermatology and medical aesthetics subsidiary of China Medical System Holdings (CMS). The company focuses on the full lifecycle of aesthetic and dermatological health, ranging from prescription drugs for chronic skin diseases to medical aesthetic devices and professional skincare. Its core portfolio includes innovative treatments such as Tildrakizumab for psoriasis and Ruxolitinib cream for vitiligo, alongside a variety of energy-based aesthetic devices. By leveraging CMS's robust commercialization platform and global sourcing capabilities, CMS Aesthetics aims to become a leading player in the Chinese medical aesthetics market. The company integrates R&D, global supply chain management, and a professional academic promotion system to serve dermatologists and aesthetic practitioners.